Earlier studies in this laboratory have shown the potential of artemisinin-curcumin combination therapy in experimental malaria. In a parasite recrudescence model in mice infected with Plasmodium berghei (ANKA), a single dose of alpha,beta-arteether (ART) with three oral doses of curcumin prevented recrudescence, providing almost 95% protection. The parasites were completely cleared in blood with ART-alone (AE) or ART+curcumin (AC) treatments in the short-term, although the clearance was faster in the latter case involving increased ROS generation. But, parasites in liver and spleen were not cleared in AE or AC treatments, perhaps, serving as a reservoir for recrudescence. Parasitemia in blood reached up to 60% in AE-treated mice during the recrudescence phase, leading to death of animals. A transient increase of up to 2–3% parasitemia was observed in AC-treatment, leading to protection and reversal of splenomegaly. A striking increase in spleen mRNA levels for TLR2, IL-10 and IgG-subclass antibodies but a decrease in those for INFγ and IL-12 was observed in AC-treatment. There was a striking increase in IL-10 and IgG subclass antibody levels but a decrease in INFγ levels in sera leading to protection against recrudescence. AC-treatment failed to protect against recrudescence in TLR2？/？ and IL-10？/？ animals. IL-10 injection to AE-treated wild type mice and AC-treated TLR2？/？ mice was able to prolong survival. Blood from the recrudescence phase in AE-treatment, but not from AC-treatment, was able to reinfect and kill na？ve animals. Sera from the recrudescence phase of AC-treated animals reacted with several parasite proteins compared to that from AE-treated animals. It is proposed that activation of TLR2-mediated innate immune response leading to enhanced IL-10 production and generation of anti-parasite antibodies contribute to protective immunity in AC-treated mice. These results indicate a potential for curcumin-based combination therapy to be tested for prevention of recrudescence in falciparum and relapse in vivax malaria.
References
[1]
Yeung S, Pongtavornpinyo W, Hastings IM, Mills AJ, White NJ (2004) Antimalarial drug resistance artemisinin-based combination therapy and the contribution of modeling to elucidating policy choices. Am J Trop Med Hyg 71: 179–186.
[2]
White NJ (1999) Antimalarial drug resistance and combination therapy. Phil Trans R Soc Lond B Biol Sci 354: 737–749.
[3]
Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, et al. (2009) Artemisinin Resistance in Plasmodium falciparum Malaria. N Engl J Med 361: 455–467.
[4]
Nosten F, White NJ (2009) Artemisinin-based combination treatment of falciparum malaria. Am J Trop Med Hyg 77: 181–192.
[5]
Kamya MR, Yeka A, Bukirwa H, Lugemma M, Rwakimari JB, et al. (2007) Artemether-lumefantrine versus dihydroartemisinin-piperaqine for treatment of malaria: a randomized trial. PLoS Clin Trials 2: e20.
[6]
Karema C, Fanello CI, Van Overmeir C, Van Geertruyden JP, van Doren W, et al. (2006) Safety and efficacy of dihydroaretmisinin/piperaquine (Artekin), for the treatment of uncomplicated Plasmodium falciparum malaria in Rwanden children. Trans R Soc Trop Med Hyg 101: 1105–1111.
[7]
Reddy RC, Vathasala PG, Keshamouni VG, Padmanaban G, Rangarajan PN (2006) Curcumin for malaria therapy. Biochem Biophys Res Comm 326: 472–474.
[8]
Nanadakumar DN, Nagaraj VA, Vathsala PG, Rangarajan PN, Padmanaban G (2006) Curcumin - artemisinin combination therapy for malaria. Antimicrob Agents Chem 50: 1859–1860.
[9]
Rougemont M, Van Saanen M, Sahli R, Hinrikson HP, Bille J, et al. (2004) Detection of four Plasmodium species from humans by 18S rRNA gene subunit -based and species -specific real time PCR assays. J Clin Microbiol 42: 5636–5643.
[10]
Martinelli A, Rodrigues LA, Cravo P (2008) Plasmodium chabaudi: Efficacy of artemisinin+curcumin combination treatment on a clone selected for artemisinin resistance in mice. Exp Parasitol 119: 304–307.
[11]
Akhtar F, Rizvi MA, Kar SK (2011) Oral delivery of curcumin bound to chitosan nanoparticles cured Plasmodium yoelli infected mice. Biotech Adv BA-06408.
[12]
Landau I, Chabaud AG, Mora-SilveraI E, Coqulin F, Boulard Y, et al. (1999) Survival of rodent malaria merozoites in the lymphatic network: Potential role in chronicity of the infection. Parasite 6: 311–322.
[13]
Wykes MN, Kay JG, Manderson A, Liu XQ, Brown DL, et al. (2011) Rodent blood-stage Plasmodium survive in dendrtic cells that infect na？ve mice. Proc Natl Acad Sci USA 108: 11205–11210.
[14]
Song Y, Sonawane ND, Qian L, Pedemonte N, Galietta LJV, et al. (2004) Evidence against the rescue of defective DeltaF508-CFTR cellular processing by curcumin in cell culture and mouse models. J Biol Chem 279: 40629–40633.
[15]
May LA, Tourkina E, Hoffman SR, Dix TA (2004) Detection and quantitation of curcumin in mouse lung cell cultures by matrix-assisted laser desorption ionization time of flight mass spectrometry. Anal Biochem 337: 62–69.
[16]
Sarciron ME, Saccharin C, Petavy AF, Peyron F (2000) Effects of Artesunate, Dihydroartemisinin, and an Artesunate-Dihydroartemisinin combination against Toxoplasma gondii. Am J Trop Med Hyg 62: 73–76.
[17]
Joe B, Vijayakumar B, Lokesh BR (2004) Biological properties of curcumin-cellular and molecular mechanisms of action. Crit Rev Food Sci Nutri 44: 97–111.
[18]
Cui L, Miao J, Cui L (2007) Cytotoxic effect of curcumin on malaria parasite Plasmodium falciparum. Inhibition of histone acetylation and generation of reactive oxygen species. Antimicrob Agents Chemother 51: 488–494.
[19]
Krishnegowda G, Hajjar AM, Zhu J, Douglass EJ, Uematsu S, et al. (2005) Induction of proinflammatory responses in macrophages by the glycosylphosphatidylinositols of Plasmodium falciparum: cell signaling receptors, glycosylphosphatidylinositol (GPI) structural requirement, and regulation of GPI activity. J Biol Chem 280: 8606–8616.
[20]
Parroche P, Lauw FN, Goutagny N, Latz E, Monks BG, et al. (2007) Malaria hemozoin is immunologically inert but radically enhances innate responses by presenting malaria DNA to Toll-like receptor 9. Proc Natl Acad Sci USA 104: 1919–1924.
[21]
Franklin BS, Parroche P, Ataíde MA, Lauw F, Ropert C, et al. (2009) Malaria primes the innate immune response due to interferon-γ induced enhancement of toll-like receptor expression and function. Proc Natl Acad Sci USA 106: 5789–5794.
[22]
Grau GE, Taylor TE, Molyneux ME, Wirima JJ, Vassalli P, et al. (1989) Tumor necrosis factor and disease severity in children with falciparum malaria. N Engl J Med 320: 1586–1591.
[23]
Awandare GA, Goka B, Boeuf P, Tetteh JK, Kurtzhals JA, et al. (2006) Increased levels of inflammatory mediators in children with severe Plasmodium falciparum malaria with respiratory distress. J Infect Dis 194: 1438–1446.
[24]
Nie CQ, Bernard NJ, Schofield BL, Hansen DS (2007) CD4+ CD25+ Regulatory T cells suppress CD4+ T-Cell function and inhibit the development of Plasmodium berghei - specific TH1 responses involved in cerebral malaria pathogenesis. Infect Immun 75: 2275–2282.
[25]
Riley EM, Wahl S, Schofield L (2006) Regulating immunity to malaria Parasite. Immunol 28: 35–49.
[26]
Shibui A, Hozumi N, Shiraishi C, Sato Y, Iida H, et al. (2009) CD4+ T cell response in early erythrocytic stage malaria: Plasmodium berghei infection in BALB/c and C57BL/6 mice. Parasitol Res 105: 281–286.
[27]
Su Z, Stevenson MM (2002) IL-12 is required for antibody-mediated protective immunity against blood stage Plasmodium chabaudi HS malarial infection in mice. J Immunol 168: 1348–1355.
[28]
Ma s-h, Aheng LI, Liu Y-J, Guo S-Y, Feng H, et al. (2007) Plasmodium Yoelii: Influence of antimalarial agent on acquision of immunity in BALB/C and DBA/2 mice. Exptl Parasitol 116: 266–272.
[29]
Saraiva M, O'Garra A (2010) The regulation of IL-10 production by immune cells. Nat Rev Immunol 10: 170–181.
[30]
Niikura M, Kamiya S, Nakane A, Kita K, Kobayashi F (2010) IL-10 plays a crucial role for the protection of experimental cerebral malaria by co-infection with non-lethal malaria parasites. Int J Parasitol 40: 101–108.
[31]
Ang KKH, Holmes MJ, Kara UAK (2001) Immune-mediated parasite clearance in mice infected with Plasmodium berghei treatment with manzamine A. Parasitol Res 87: 715–721.
[32]
Nunes JK, Starnbach MN, Wirth DF (2009) Secreted antibody is required for immunity to Plasmodium berghei. Infect Immunity 77: 414–418.
[33]
Ringman JM, Frautschy SA, Cole GM, Cummings JL (2005) A potential role of the curry spice curcumin in Alzheimer's disease. Curr Alzheimer Res 2: 131–136.
[34]
Egan ME, Pearson M, Weiner SA, Rajendran V, Rubin D, et al. (2004) Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science 304: 600–602.
[35]
Jagetia GC, Aggarwal BB (2007) “Spicing up” the immune system by curcumin. J Clin Immunol 27: 19–35.
[36]
Wells TN, Burrows JN, Baird JK (2010) Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination. Trends Parasitol 26: 145–151.
[37]
Waknine-Grinberg JH, McQuillan JA, Hunt N, Ginsburg H, Golenser J (2010) Modulation of cerebral malaria by fasudil and other immune-modifying compounds. Exp Parasitol 125: 141–146.
[38]
Mimche PN, Taramelli D, Vivas L (2011) The plant-based immunomodulator curcumin as a potential candidate for the development of an adjunctive therapy for cerebral malaria. Malaria J 10: Suppl 1S10 1–9.
[39]
Tripathi AK, Khan SI, Walker LA, Tekwani BLSpectrophotometric determination of de novo hemozoin/beta-hematin formation in an in vitro assay. Anal Biochem 325: 85–91.
